Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Background and Objectives: In recent years, the effectiveness of chemotherapy after immune checkpoint inhibitor administration has attracted attention in various cancers, including head and neck cancers. However, individual assessments of the administered chemotherapy regimens are insufficient. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Shinsuke, Toyoma, Satoshi, Kawasaki, Yohei, Koizumi, Koh, Iikawa, Nobuko, Shiina, Kazuhiro, Endo, Tentaro, Abe, Tomoe, Kouga, Teppei, Yamada, Takechiyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621992/
https://www.ncbi.nlm.nih.gov/pubmed/34833369
http://dx.doi.org/10.3390/medicina57111151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621992/
https://www.ncbi.nlm.nih.gov/pubmed/34833369
http://dx.doi.org/10.3390/medicina57111151

Ejemplares similares